Skip to main content
. Author manuscript; available in PMC: 2017 Jun 26.
Published in final edited form as: Nature. 2016 May 11;533(7603):411–415. doi: 10.1038/nature17662

Table 1.

Fasting plasma concentration of pro-neurotensin (pro-NT) in relation to obesity, insulin resistance and incidence of new-onset obesity in human subjects (Malmö Diet and Cancer Cardiovascular Cohort, MDC-CC)

N total / N Cases Odds ratio (95% confidence interval) p for trend
Pro-NT Quartile 1 Pro-NT Quartile 2 Pro-NT Quartile 3 Pro-NT Quartile 4
Prevalent obesity 4626 / 604 1.0 (ref) 1.00 (0.78–1.29) 1.13 (0.88–1.45) 1.34 (1.05–1.70) 0.01
Prevalent abdominal obesity 4625 / 1769 1.0 (ref) 1.07 (0.90–1.27) 1.23 (1.04–1.46) 1.30 (1.09–1.54) 0.001
Prevalent insulin resistance 4468 / 1140 1.0 (ref) 1.30 (1.06–1.59) 1.43 (1.17–1.74) 1.70 (1.39–2.06) <0.0001
New-onset obesity 2594 / 333 1.0 (ref) 1.41 (0.95–2.10) 1.79 (1.21–2.65) 2.05 (1.38–3.06) <0.0001

N total / N cases denotes total number of subjects in the analysis divided by the number of cases with listed obesity or insulin resistance phenotype. Pro-NT Quartiles 1–4 define the MDC-CC population quartiles (lowest to highest) with median (range) baseline fasting plasma pro-NT concentrations (pmol/L) of 60.1 (3.3–75.9), 89.3 (75.9–105), 123 (105–149) and 190 (149–1155), respectively. Data are presented as odds ratios (95% confidence intervals), and subjects belonging to the lowest quartile of pro-NT were defined as the reference group (odds ratio =1). p for trend denotes the p-value for linear trend over quartiles 1–4. Logistic regression models were used for comparisons between quartiles and linear trends over quartiles (see Methods).